Azithromycin and Hydroxychloroquine Prescriptions on the Rise Globally – Survey
The most recent update of a survey of some 4016 medical doctors world-wide indicates a rise in prescriptions of of Azithromycin and Hydroxychloroquine for COVID-19 treatment. The survey was conducted by the Sermo institute and covered the April 3 to 9 period.
The top three treatments that doctors reported having prescribed were Azithromycin (58%), Hydroxychloroquine (50%), and Bronchodilators (48%); traditional Chinese medicine has been used by 67% of physicians in China.
Italy and France had the highest increase in COVID treaters having prescribed Hydroxychloroquine wave over wave; an increase from 50% to 83% for Italy and an increase from 20% to 50% for France.
Regarding perceived treatment efficacy, physicians who treat COVID patients in Italy, Spain, France, and China have higher perceptions of Hydroxychloroquine’s efficacy vs the US (~50% vs 29%).
The top treatments that have been used/seen used and reported as very or extremely effective among COVID treaters (N= 1337) include: 46% plasma from recovered patients (n=363); 40% Hydroxychloroquine (n=875); 38% high dose steroids during a cytokine storm (n=556).
Regarding the most popular Hydroxychloroquine dosage regimen, 75% report using 400mg BID on day one (800mg total), then 400 mg daily for 4-5 days, while 10% report using 600mg BID on day one (1,200mg total), then 400 mg daily for 4 days
The survey covers 4016 physicians in 30 countries, namely United States, Canada, Argentina, Brazil, Mexico, Germany, Italy, the United Kingdom, France, Spain, Belgium, the Netherlands, Sweden, Turkey, Poland, Russia, Finland, Ireland, Switzerland, Austria, Denmark, Norway, Greece, Taiwan, Japan, South Korea, Australia, China, India, and Hong Kong.
Note that among those, countries such as the UK and Canada are opposing treatments such as the the Azithromycin and Hydroxychloroquine combination. If medical doctors in such countries had the right to prescribe them, the global numbers would be even more in favor of these drugs.
See Details: https://app.sermo.com/covid19-barometer?utm_campaign=wwwsermo_covid19
Media Release: https://www.sermo.com/press-releases/category/week-of-0413/